Literature DB >> 20425541

Immuno- and gene-therapeutic strategies targeted against cancer (mainly focusing on pancreatic cancer).

Kiyoshi Yoshimura1, Kelly Olino, Barish H Edil, Richard D Schulick, Masaaki Oka.   

Abstract

Current treatment modalities of surgical resection and chemotherapy against cancers have improved survival. However, mortality from tumor recurrence remains high. Immunotherapy and gene therapy are potential additions to the treatment arsenal in the care of cancer patients. These novel therapeutic approaches need further investigation in in vitro and in vivo models as they are developed for potential use in humans. Here we reviewed immunotherapies and gene therapies that included clinical trials against cancers (mainly focusing on pancreatic cancer) suggesting the strong possibility of using these novel approaches.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20425541     DOI： 10.1007/s00595-009-4120-8

Source DB:  PubMed          Journal:  Surg Today        ISSN： 0941-1291            Impact factor:   2.540


  51 in total

1.  Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience.

Authors:  C J Yeo; R A Abrams; L B Grochow; T A Sohn; S E Ord; R H Hruban; M L Zahurak; W C Dooley; J Coleman; P K Sauter; H A Pitt; K D Lillemoe; J L Cameron
Journal:  Ann Surg       Date:  1997-05       Impact factor: 12.969

2.  Improving results of pancreaticoduodenectomy for pancreatic cancer.

Authors:  C J Yeo; J L Cameron
Journal:  World J Surg       Date:  1999-09       Impact factor: 3.352

3.  Adenovirus-mediated anti-K-ras ribozyme induces apoptosis and growth suppression of human pancreatic carcinoma.

Authors:  T Tsuchida; H Kijima; S Hori; Y Oshika; T Tokunaga; K Kawai; H Yamazaki; Y Ueyama; K J Scanlon; N Tamaoki; M Nakamura
Journal:  Cancer Gene Ther       Date:  2000-03       Impact factor: 5.987

4.  Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection.

Authors:  M H Kalser; S S Ellenberg
Journal:  Arch Surg       Date:  1985-08

5.  Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity.

Authors:  G Dranoff; E Jaffee; A Lazenby; P Golumbek; H Levitsky; K Brose; V Jackson; H Hamada; D Pardoll; R C Mulligan
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-15       Impact factor: 11.205

6.  Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials.

Authors:  E M Jaffee; M Schutte; J Gossett; L A Morsberger; A J Adler; M Thomas; T F Greten; R H Hruban; C J Yeo; C A Griffin
Journal:  Cancer J Sci Am       Date:  1998 May-Jun

Review 7.  CTLA-4: new insights into its biological function and use in tumor immunotherapy.

Authors:  Jackson G Egen; Michael S Kuhns; James P Allison
Journal:  Nat Immunol       Date:  2002-07       Impact factor: 25.606

Review 8.  In situ use of suicide genes for cancer therapy.

Authors:  S M Freeman; K A Whartenby; J L Freeman; C N Abboud; A J Marrogi
Journal:  Semin Oncol       Date:  1996-02       Impact factor: 4.929

Review 9.  Update on anti-CTLA-4 antibodies in clinical trials.

Authors:  Lee F Langer; Timothy M Clay; Michael A Morse
Journal:  Expert Opin Biol Ther       Date:  2007-08       Impact factor: 4.388

Review 10.  Influence of the bystander effect on HSV-tk/GCV gene therapy. A review.

Authors:  Ingrid J van Dillen; Nanno H Mulder; Willem Vaalburg; Erik F J de Vries; Geke A P Hospers
Journal:  Curr Gene Ther       Date:  2002-09       Impact factor: 4.391
View more
  1 in total

Review 1.  Biological mechanism and clinical effect of protein-bound polysaccharide K (KRESTIN(®)): review of development and future perspectives.

Authors:  Yoshihiko Maehara; Shunichi Tsujitani; Hiroshi Saeki; Eiji Oki; Keiji Yoshinaga; Yasunori Emi; Masaru Morita; Shunji Kohnoe; Yoshihiro Kakeji; Tokujiro Yano; Hideo Baba
Journal:  Surg Today       Date:  2011-12-06       Impact factor: 2.549
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.